D.E. Shaw & Co’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-30,635
| Closed | -$148K | – | 4371 |
|
|
2020
Q1 | $148K | Buy |
+30,635
| New | +$199K | ﹤0.01% | 3721 |
|
|
2019
Q1 | – | Sell |
-17,675
| Closed | -$168K | – | 4065 |
|
|
2018
Q4 | $168K | Sell |
17,675
-85,939
| -83% | -$1.11M | ﹤0.01% | 3582 |
|
|
2018
Q3 | $1.72M | Sell |
103,614
-91,678
| -47% | -$1.47M | ﹤0.01% | 2300 |
|
|
2018
Q2 | $3.13M | Sell |
195,292
-55,129
| -22% | -$984K | ﹤0.01% | 1886 |
|
|
2018
Q1 | $3.83M | Buy |
250,421
+57,588
| +30% | +$898K | 0.01% | 1586 |
|
|
2017
Q4 | $3.01M | Buy |
192,833
+105,539
| +121% | +$1.41M | ﹤0.01% | 1846 |
|
|
2017
Q3 | $969K | Sell |
87,294
-14,990
| -15% | -$141K | ﹤0.01% | 2507 |
|
|
2017
Q2 | $941K | Buy |
102,284
+88,782
| +658% | +$740K | ﹤0.01% | 2458 |
|
|
2017
Q1 | $115K | Sell |
13,502
-17,755
| -57% | -$162K | ﹤0.01% | 3186 |
|
|
2016
Q4 | $334K | Buy |
31,257
+2,611
| +9% | +$31.6K | ﹤0.01% | 3075 |
|
|
2016
Q3 | $310K | Sell |
28,646
-4,794
| -14% | -$39K | ﹤0.01% | 3036 |
|
|
2016
Q2 | $226K | Sell |
33,440
-16,157
| -33% | -$102K | ﹤0.01% | 3149 |
|
|
2016
Q1 | $231K | Sell |
49,597
-3,432
| -6% | -$16.8K | ﹤0.01% | 3135 |
|
|
2015
Q4 | $335K | Buy |
+53,029
| New | +$430K | ﹤0.01% | 3316 |
|
|
2015
Q3 | – | Sell |
-12,342
| Closed | -$145K | – | 3997 |
|
|
2015
Q2 | $145K | Buy |
+12,342
| New | +$171K | ﹤0.01% | 3621 |
|
|
2014
Q1 | – | Sell |
-22,002
| Closed | -$431K | – | 4769 |
|
|
2013
Q4 | $431K | Sell |
22,002
-9,532
| -30% | -$254K | ﹤0.01% | 3812 |
|
|
2013
Q3 | $1.43M | Sell |
31,534
-45,644
| -59% | -$1.49M | ﹤0.01% | 2722 |
|
|
2013
Q2 | $1.84M | Buy |
+77,178
| New | +$1.23M | ﹤0.01% | 2204 |
|
D.E. Shaw & Co's STML Position: Q2 2020 in Review
D.E. Shaw & Co sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 30,635 shares — an estimated $148K sold.
D.E. Shaw & Co first reported a position in STML in Q2 2013 and held it in 18 quarters. The position peaked at $3.83M in Q1 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- D.E. Shaw & Co reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- D.E. Shaw & Co sold 30,635 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $148K.
- D.E. Shaw & Co first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
- D.E. Shaw & Co's Stemline Therapeutics, Inc. position peaked at $3.83M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on D.E. Shaw & Co's 13F filing for Q2 2020, filed 14 Aug 2020.